ZA201902608B - Methods of treating obesity with anti¿angptl8 antibodies - Google Patents

Methods of treating obesity with anti¿angptl8 antibodies

Info

Publication number
ZA201902608B
ZA201902608B ZA2019/02608A ZA201902608A ZA201902608B ZA 201902608 B ZA201902608 B ZA 201902608B ZA 2019/02608 A ZA2019/02608 A ZA 2019/02608A ZA 201902608 A ZA201902608 A ZA 201902608A ZA 201902608 B ZA201902608 B ZA 201902608B
Authority
ZA
South Africa
Prior art keywords
methods
treating obesity
angptl8 antibodies
angptl8
antibodies
Prior art date
Application number
ZA2019/02608A
Other languages
English (en)
Inventor
Viktoria Gusarova
Jesper Gromada
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ZA201902608B publication Critical patent/ZA201902608B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2019/02608A 2016-11-17 2019-04-24 Methods of treating obesity with anti¿angptl8 antibodies ZA201902608B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423639P 2016-11-17 2016-11-17
PCT/US2017/062103 WO2018094112A1 (en) 2016-11-17 2017-11-16 Methods of treating obesity with anti-angptl8 antibodies

Publications (1)

Publication Number Publication Date
ZA201902608B true ZA201902608B (en) 2020-07-29

Family

ID=60655071

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/02608A ZA201902608B (en) 2016-11-17 2019-04-24 Methods of treating obesity with anti¿angptl8 antibodies

Country Status (13)

Country Link
US (1) US10442856B2 (enExample)
EP (1) EP3541839A1 (enExample)
JP (1) JP7133551B2 (enExample)
KR (1) KR20190078650A (enExample)
CN (1) CN110036029A (enExample)
AU (1) AU2017363143B2 (enExample)
CA (1) CA3044249A1 (enExample)
EA (1) EA201991203A1 (enExample)
IL (1) IL266564A (enExample)
MA (1) MA46842A (enExample)
MX (1) MX382035B (enExample)
WO (1) WO2018094112A1 (enExample)
ZA (1) ZA201902608B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954082A1 (en) 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
EP3749691A4 (en) 2017-11-10 2021-10-27 NGM Biopharmaceuticals, Inc. ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111690058B (zh) * 2020-03-30 2021-02-05 三优生物医药(上海)有限公司 针对冠状病毒的具有中和活性的抗体及其用途
CN119367545B (zh) * 2025-01-02 2025-04-08 山东第一医科大学(山东省医学科学院) 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
KR20050004240A (ko) 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
BRPI0812384A2 (pt) 2007-05-22 2014-12-02 Novartis Ag Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CA2954082A1 (en) 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PL3439689T3 (pl) 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3

Also Published As

Publication number Publication date
CA3044249A1 (en) 2018-05-24
CN110036029A (zh) 2019-07-19
US20180134781A1 (en) 2018-05-17
MX382035B (es) 2025-03-13
IL266564A (en) 2019-07-31
MA46842A (fr) 2019-09-25
US10442856B2 (en) 2019-10-15
JP2020500852A (ja) 2020-01-16
KR20190078650A (ko) 2019-07-04
AU2017363143B2 (en) 2022-07-28
EP3541839A1 (en) 2019-09-25
EA201991203A1 (ru) 2019-10-31
JP7133551B2 (ja) 2022-09-08
WO2018094112A1 (en) 2018-05-24
MX2019005651A (es) 2019-11-12
AU2017363143A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
ZA201800352B (en) Anti¿angptl8 antibodies and uses thereof
ZA201801943B (en) Anti¿lag3 antibodies and uses thereof
ZA201900193B (en) Anti¿pd¿l1 antibodies and uses thereof
ZA201801673B (en) Optimized anti¿cd3 bispecific antibodies and uses thereof
ZA201801432B (en) Anti¿lag¿3 antibodies
ZA201808603B (en) Anti¿zika virus antibodies and methods of use
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
IL251537A0 (en) Human anti-ox40 antibodies and their uses
ZA201606630B (en) Anti-ox40 antibodies and methods of use
PL3426686T3 (pl) Humanizowane przeciwciała anty-pacap i ich zastosowanie
IL266564A (en) Methods for treating obesity with anti-angptl8 antibodies
EP3223865A4 (en) Methods of treating conditions with antibodies that bind b7-h4
IL267519A (en) Methods of treatment by antibodies against factor xi/xia
IL250724A0 (en) Methods for treating multiple myeloma with immunomodulatory compounds in combination with antibodies
SG11201707886WA (en) Humanized anti-c1s antibodies and methods of use thereof
ZA201806293B (en) New anti¿sirpa antibodies and their therapeutic applications
PL3445785T3 (pl) Humanizowane przeciwciała anty-clever-1 i ich zastosowanie
IL249540B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
IL265568A (en) Methods for treating TIM-3 elevation
HK40014182A (en) Methods of treating obesity with anti-angptl8 antibodies